MUC1 immunotherapy against a metastatic mammary adenocarcinoma model: Importance of IFN-gamma

1. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991; 49: 281–355.10.1016/S0065-2776(08)60778-6Search in Google Scholar

2. Melief CJ. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res. 1992; 58: 143–75.10.1016/S0065-230X(08)60294-8Search in Google Scholar

3. Leung HT, Linsley PS. The CD28 costimulatory pathway. Ther Immunol. 1994; 1: 217–28.Search in Google Scholar

4. Leung J, Suh WK. The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. Immune Netw. 2014; 14: 265–76.10.4110/in.2014.14.6.265Search in Google Scholar

5. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016; 39: 44–51.10.1016/j.coi.2015.12.007Search in Google Scholar

6. Garrido F, Romero I, Aptsiauri N, Garcia-Lora AM. Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype. Int J Cancer. 2016; 138: 271–80.10.1002/ijc.29375Search in Google Scholar

7. Nawrocki S, Mackiewicz A. Genetically modified tumour vaccines--where we are today. Cancer Treat Rev. 1999; 25: 29–46.10.1053/ctrv.1998.0104Search in Google Scholar

8. Mandai M. PD-1/PD-L1 blockage in cancer treatment-from basic research to clinical application. Int J Clin Oncol. 2016.10.1007/s10147-016-0969-xSearch in Google Scholar

9. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumour development. Immunol Today. 1993; 14: 491–9.10.1016/0167-5699(93)90264-LSearch in Google Scholar

10. Torres LM, Cabrera T, Concha A, Oliva MR, Ruiz-Cabello F, Garrido F. HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix. Tissue Antigens. 1993; 41: 65–71.10.1111/j.1399-0039.1993.tb01981.x8386400Search in Google Scholar

11. Vlkova V, Stepanek I, Hruskova V, Senigl F, Mayerova V, Sramek M, et al. Epigenetic regulations in the IFNgamma signalling pathway: IFNgamma-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes. Oncotarget. 2014; 5: 6923–35.10.18632/oncotarget.2222419617325071011Search in Google Scholar

12. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature. 1985; 315: 301–5.10.1038/315301a0Search in Google Scholar

13. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama T, et al. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity. Proc Natl Acad Sci U S A. 1989; 86: 9456–60.10.1073/pnas.86.23.9456Search in Google Scholar

14. Apostolopoulos V, Xing PX, Trapani JA, McKenzie IF. Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein. Br J Cancer. 1993; 67: 713–20.10.1038/bjc.1993.131Search in Google Scholar

15. Apostolopoulos V, Barnes N, Pietersz GA, McKenzie IF. Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. Vaccine. 2000; 18: 3174–84.10.1016/S0264-410X(00)00090-6Search in Google Scholar

16. Apostolopoulos V, Haurum JS, McKenzie IF. MUC1 peptide epitopes associated with five different H-2 class I molecules. Eur J Immunol. 1997; 27: 2579–87.10.1002/eji.1830271017Search in Google Scholar

17. Apostolopoulos V, Karanikas V, Haurum JS, McKenzie IF. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol. 1997; 159: 5211–8.Search in Google Scholar

18. Apostolopoulos V, Loveland BE, Pietersz GA, McKenzie IF. CTL in mice immunized with human mucin 1 are MHC-restricted. J Immunol. 1995; 155: 5089–94.Search in Google Scholar

19. Apostolopoulos V, Pietersz GA, Gordon S, Martinez-Pomares L, McKenzie IF. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol. 2000; 30: 1714–23.10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-CSearch in Google Scholar

20. Apostolopoulos V, Pietersz GA, Loveland BE, Sandrin MS, McKenzie IF. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A. 1995; 92: 10128–32.10.1073/pnas.92.22.10128Search in Google Scholar

21. Apostolopoulos V, Pietersz GA, Xing PX, Lees CJ, Michael M, Bishop J, et al. The immunogenicity of MUC1 peptides and fusion protein. Cancer Lett. 1995; 90: 21–6.10.1016/0304-3835(94)03673-7Search in Google Scholar

22. Lees CJ, Apostolopoulos V, Acres B, Ong CS, Popovski V, McKenzie IF. The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1. Cancer Immunol Immunother. 2000; 48: 644–52.10.1007/s002620050013Search in Google Scholar

23. Lees CJ, Apostolopoulos V, Acres B, Ramshaw I, Ramsay A, Ong CS, et al. Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. Vaccine. 2000; 19: 158–62.10.1016/S0264-410X(00)00065-7Search in Google Scholar

24. Baruch A, Hartmann M, Yoeli M, Adereth Y, Greenstein S, Stadler Y, et al. The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. Cancer research. 1999; 59: 1552–61.Search in Google Scholar

25. Baruch A, Hartmann M, Zrihan-Licht S, Greenstein S, Burstein M, Keydar I, et al. Preferential expression of novel MUC1 tumor antigen isoforms in human epithelial tumors and their tumor-potentiating function. Int J Cancer. 1997; 71: 741–9.10.1002/(SICI)1097-0215(19970529)71:5<741::AID-IJC9>3.0.CO;2-RSearch in Google Scholar

26. Acres B, Apostolopoulos V, Balloul JM, Wreschner D, Xing PX, Ali-Hadji D, et al. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol Immunother. 2000; 48: 588–94.10.1007/PL00006677Search in Google Scholar

27. Acres RB, Hareuveni M, Balloul JM, Kieny MP. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J Immunother Emphasis Tumor Immunol. 1993; 14: 136–43.10.1097/00002371-199308000-00009Search in Google Scholar

28. Xing PX, Tjandra JJ, Stacker SA, Teh JG, Thompson CH, McLaughlin PJ, et al. Monoclonal antibodies reactive with mucin expressed in breast cancer. Immunol Cell Biol. 1989; 67 (Pt 3): 183–95.10.1038/icb.1989.29Search in Google Scholar

29. Ozato K, Mayer NM, Sachs DH. Monoclonal antibodies to mouse major histocompatibility complex antigens. Transplantation. 1982; 34: 113–20.10.1097/00007890-198209000-00001Search in Google Scholar

30. Rentrop M, Knapp B, Winter H, Schweizer J. Aminoalkylsilane-treated glass slides as support for in situ hybridization of keratin cDNAs to frozen tissue sections under varying fixation and pretreatment conditions. Histochem J. 1986; 18: 271–6.10.1007/BF01676237Search in Google Scholar

31. Apostolopoulos V, Pietersz GA, McKenzie IF. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine. 1996; 14: 930–8.10.1016/0264-410X(95)00258-3Search in Google Scholar

32. Apostolopoulos V, McKenzie IF, Lees C, Matthaei KI, Young IG. A role for IL-5 in the induction of cytotoxic T lymphocytes in vivo. Eur J Immunol. 2000; 30: 1733–9.10.1002/1521-4141(200006)30:6<1733::AID-IMMU1733>3.0.CO;2-ESearch in Google Scholar

33. Apostolopoulos V, Popovski V, McKenzie IF. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP). J Immunother. 1998; 21: 109–13.10.1097/00002371-199803000-00003Search in Google Scholar

34. Apostolopoulos V, Xing PX, McKenzie IF. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens. Cancer Res. 1994; 54: 5186–93.Search in Google Scholar

35. Sgagias MK, Nieroda C, Yannelli JR, Cowan KH, Danforth DN, Jr. Upregulation of DF3, in association with ICAM-1 and MHC class II by IFN-gamma in short-term human mammary carcinoma cell cultures. Cancer Biother Radiopharm. 1996; 11: 177–85.10.1089/cbr.1996.11.177Search in Google Scholar

36. Chen L, Ashe S, Brady WA, Hellstrom I, Hellstrom KE, Ledbetter JA, et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992; 71: 1093–102.10.1016/S0092-8674(05)80059-5Search in Google Scholar

37. Chen L, Linsley PS, Hellstrom KE. Costimulation of T cells for tumor immunity. Immunol Today. 1993; 14: 483–6.10.1016/0167-5699(93)90262-JSearch in Google Scholar